Introducing the latest issue of our medical and pharmacy benefit management report

Prime Therapeutics/Magellan Rx Management (Prime/Magellan Rx) recently released the summer edition of the Magellan Rx Report, which details relevant industry topics such as payer impact and treatment approvals for pulmonary arterial hypertension, insights into the Inflation Reduction Act, an update on the Centers for Medicare & Medicaid Services (CMS) Star Ratings Program and a look at the trend of glucagon-like peptide-1 (GLP-1) receptor agonist medications for weight loss. This comes at the heels of the announcement of our industry-leading year-two research, which revealed only 1 in 7 patients stay on a GLP-1 drug for weight loss after two years.

Other key topics in the latest Magellan Rx Report include:

• Treatment landscape and payer management for paroxysmal nocturnal hemoglobinuria
• First approval and payer strategies for nonalcoholic steatohepatitis
• Approvals and updates in treating multiple sclerosis
• Opportunities for the health care application of artificial intelligence
• Drug pipeline projections and updates

Learn more about how Prime/Magellan Rx is reimagining pharmacy benefits to provide the same care we would want for our loved ones.